NV AB259

Prohibits purchasing drugs subject to federal Medicare "maximum fair price" at prices exceeding that cap, and prohibits seeking reimbursement for such drugs at rates higher than the maximum fair price (excluding pharmacy dispensing fees)

Classifies violations as deceptive trade practices subject to civil penalties up to $10,000-$15,000 per violation, but explicitly exempts violators from criminal penalties under existing deceptive trade practice law

Creates a private right of action allowing individuals harmed by violations to sue for consumer fraud, with remedies including damages, equitable relief, costs, and attorney's fees

Exempts federal employee health plans, ERISA-governed plans, and Taft-Hartley trusts from compliance, though these entities may voluntarily opt in by notifying the Director by January 1 of each year

Applies to contracts entered into or renewed after January 1, 2026, with the law becoming fully operative on that date